A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

Summary

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).

Timeline

Start

2021-03-31

Primary completion

2023-10-26

Completion

2023-10-26

Outcome

Missed primary endpoint

Stopped: “Independent Data Monitoring Committee recommended terminating the study following a pre-planned analysis as the efficacy results did not meet the pre-defined futility guidelines. There were no new safety concerns identified from this analysis.”

registry p = 0.509; Difference in percentage of responders 6.70 (95% CI -10.90 to 24.29) NCT04612790 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Benralizumab	Monoclonal antibody	—	Subcutaneous

Indications